



21 JULY, 2023
FRIDAY



08:30 - 17:30 HRS
SINGAPORE TIME



HYBRID MEETING

08:30 - 08:40 Opening Remarks
Zhang Zewen, Singapore

Session 1 - Precision Oncology in 2023

Chairperson: **Shona Nag, India | Nitesh Rohatgi, UAE**

08:40 - 08:55 How has Precision Oncology Changed the Trajectory of Oncology Therapeutics?
Zhang Zewen, Singapore

08:55 - 09:10 Agnostic Markers: Where Are We in 2023?
Jason Chan, Singapore

09:10 - 09:25 Should Tumor Profiling be Routine for all Patients with Advanced Tumors?
Nitesh Rohatgi, India

09:25 - 09:40 MONSTAR SCREEN Experience- How the Precision Oncology Programme Is Providing Insights - *Topic supported by Caris*
Mitsuho Imai-Sumida, Japan

09:40 - 10:00 **How can patients benefit from Molecular Tumor Board discussion? Challenges to implement MTB as routine practice - Satellite Symposium by Roche**
Iain Tan, Singapore

10:00 - 10:20 Coffee Break & Networking

Session 2 - Liquid Biopsy: Where Are We in 2023?

Chairperson: **Choo Su Pin, Singapore | Nitesh Rohatgi, India**

10:20 - 10:40 Evolving Role of Liquid Biopsy in the Clinic: Will it Replace Tissue Profiling?
Tony Mok, Hong Kong

10:40 - 10:55 MRD Testing: Is this Practice Changing in 2023?
Aaron Tan, Singapore

10:55 - 11:25 Tumor Board: Challenging Cases using Liquid Biopsy

Moderator: **Evelyn Wong, Singapore**

Panellist: **Kumar Prabhash, India | Shona Nag, India | Nitesh Rohatgi, India | Aaron Tan, Singapore | Shaheenah Dawood, UAE**

11:25 - 11:45 **Q & A**

Session 3 - BRCA: Germline Genetics in 2023


Chairperson: **Shona Nag, India | Zhang Zewen, Singapore**

11:45 - 12:00 Cancer risk and management of individuals with germline pathogenic variant in PALB2
Li Shao-Tzu, Singapore

12:00 - 12:15 Should Everyone get Expanded Germline Genetic Testing?
Sowmya Jonnagadla, Singapore

12:15 - 12:30 Clinical interpretation and approach to variant of uncertain significance
Manasadevi Karthikeyan, Singapore

12:30 - 13:30 Lunch Break & Networking





21 JULY, 2023
FRIDAY



08:30 - 17:30 HRS
SINGAPORE TIME



HYBRID MEETING

Session 4 - Molecular Tumor Boards: Precision Oncology at its Best

Chairperson:	Samuel Ow, Singapore
13:30 - 13:50	The Basics of Reading a Profiling Report: What You Need to know on Monday in the Clinic? Sanjay Popat, United Kingdom
13:50 - 14:05	Precision Oncology and GU Tumors Johan Chan, Singapore
14:05 - 14:35	GU Molecular Tumor Board Moderator: Tan Wei Chong, Singapore Panellist: Johan Chan, Singapore Kenneth Chen, Singapore Tanujaa Rajasekaran, Singapore Robert Walsh, Singapore
14:35 - 15:05	A new paradigm in Cervical Cancer management: Immunotherapy and Biomarker considerations - <i>Satellite Symposium by MSD</i> Chairperson: Jack Chan, Singapore Speaker: Krishnansu S. Tewari, USA
15:05 - 15:20	Precision Oncology and Gynae Oncology David Tan, Singapore
15:20 - 15:50	Gynae Oncology Molecular Tumor Board Moderator: Frances Victoria F. Que, Philippines Panellist: Jack Chan, Singapore David Tan, Singapore Ryan Tan, Singapore Felicia Chin, Singapore
15:50 - 16:00	Coffee Break
16:00 - 16:15	Precision Oncology and Breast Cancer Lee Soo Chin, Singapore
16:15 - 16:45	Breast Cancer Molecular Tumor Board Moderator: Ma Jun, Singapore Panellist: Raymond Ng, Singapore Joline Lim, Singapore Lee Soo Chin, Singapore Shona Nag, India Chikako Shimizu, Japan Jack Chan, Singapore
16:45 - 17:00	Precision Oncology and GI Cancer Vineet Talwar, India
17:00 - 17:30	GI Cancer Molecular Tumor Board Moderator: Han Shuting, Singapore Panellist: Choo Su Pin, Singapore Joycelyn Lee, Singapore Lee Suat Ying, Singapore Faye Lim, Singapore Chee Cheng Ean, Singapore
17:30	Closing Remarks





22 JULY, 2023
SATURDAY



08:30 - 13:45 HRS
SINGAPORE TIME



HYBRID MEETING

08:00 – 08:30 Registration and Welcome Coffee

Session 1: Integrating IO Therapy for Early and Advanced Lung Cancer

Chairperson: Nitesh Rohatgi, India | Kumar Prabhash, India

08:30 - 08:50 Neoadjuvant IO Therapy: A New Revolution in Immunotherapy
Daniel Tan, Singapore

08:50 - 09:10 Optimizing IO therapy in the Advanced Setting: Where are We in 2023?
Sanjay Popat, UK

09:10 - 10:00 Tumor Board: Optimal integration of IO therapy in lung cancer

Moderator: Kumar Prabhash, India

Panellist: Tan Wei Chong, Singapore | Toh Chee Keong, Singapore |
Daniel Tan, Singapore | Jens Samol, Singapore | Aaron Tan, Singapore |
Nitesh Rohatgi, India

10:00 - 10:30 Coffee Break & Networking

10:30 - 10:50 **Clinical considerations and treatment options for advanced non-small cell lung cancer post TKI progression** – *Satellite Symposium by Roche*
Tony Mok, Hong Kong

Session 2: Targeted Therapy and Lung Cancer

Chairperson: Kumar Prabhash, India


10:50 - 11:05 Cancer Patient Journey in the Digital Healthcare
Tae-Won Kim, South Korea

11:05 - 11:20 Current Landscape of Therapeutic Resistance in Lung Cancer and Strategies to Overcome Them?
Nitesh Rohatgi, India

11:20 - 12:00 Tumor Board: Precision Oncology and Lung Cancer

Moderator: Tan Wei Chong, Singapore

Panellist: Kevin Chua, Singapore | Chia Puey Ling, Singapore | Jens Samol, Singapore |
Aaron Tan, Singapore | Kumar Prabhash, India





22 JULY, 2023
SATURDAY



08:30 - 13:45 HRS
SINGAPORE TIME



HYBRID MEETING

12:00 - 12:45

Advancing Early IO in Lung Cancer – Satellite Symposium by AstraZeneca

Opening Remarks

Daniel Tan, Singapore

The evolving landscape of neoadjuvant/adjuvant immunotherapies

Tony Mok, Hong Kong

Surgeon's perspective on resectability and incorporating new neoadj/adj therapies in treatment practice

Aneez Ahmed, Singapore

Panel Discussion and Q & A

12:45 - 13:45

Closing Remarks, Lunch Break & Networking

